CLINICAL TRIALS PROFILE FOR VICTRELIS

All Clinical Trials for VICTRELIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00959699 ↗	A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2009-11-01	The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC) plus weight-based dosing (WBD) of ribavirin (RBV) (600 mg/day to 1400 mg/day) PO to therapy with PegIFN-2b + RBV alone in adult participants coinfected with human immunodeficiency virus (HIV) and previously untreated chronic hepatitis C virus (HCV) genotype 1. Boceprevir is a potent, orally administered, novel serine protease inhibitor, specifically designed to inhibit the HCV nonstructural protein 3 (NS3) protease and, thereby, inhibit viral replication in HCV-infected host cells. The mechanism of inhibition represents a new mechanism of action compared to both interferon alfa and ribavirin. Based on previous experience with PegIFN-2b and RBV in combination with boceprevir in the HCV-monoinfected population, this combination treatment is expected to provide significant benefit to the HIV/HCV coinfected population. Given the high unmet medical need of these participants and the benefit of the addition of boceprevir to PegIFN-2b/RBV, it is important to demonstrate the safety and efficacy of boceprevir in combination with PegIFN-2b/RBV in participants coinfected with HIV/HCV. This is a randomized, multi-center trial, double-blinded for boceprevir or placebo in combination with open-label PegIFN-2b/RBV in participants coinfected with HIV and previously untreated chronic HCV (genotype 1), to be conducted in conformance with Good Clinical Practice (GCP). This trial consists of two arms, one control arm (Arm 1) and one experimental arm (Arm 2). Participants in the control arm (Arm 1) may receive boceprevir/PegIFN-2b/RBV via a crossover arm.
NCT01353911 ↗	Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2011-06-27	This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants with chronic hepatitis C.
NCT01390844 ↗	Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2011-10-21	This study will assess the efficacy of boceprevir (BOC) in combination with PegIntron (pegylated interferon alfa-2b) (PEG) and ribavirin (RBV) in response guided therapy compared to the efficacy of standard-of-care therapy alone in adult subjects with chronic hepatitis C (CHC) genotype 1 who failed prior treatment with pegylated interferon and RBV in the Asia Pacific population. The primary hypothesis is that the proportion of participants achieving sustained virologic response in the experimental therapy regimen (BOC/PEG+RBV) is superior to that in the control arm (Placebo/PEG+RBV), in the Full Analysis Set (FAS) population.
NCT01465516 ↗	Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir	Terminated	Arrowhead Regional Medical Center		2011-11-01	Hypothesis Response guided therapy improves significantly the overall SVR in Hispanics compared to historical control. There is no difference in SVR between patients with an undetectable HCV RNA at week 8 and week 28 who received a 4 week lead-in of PR plus 24 weeks of PR+BOC based treatment and patients with detectable HCV RNA at week 8 and undetectable HCV RNA at week 24 who received a lead-in of PR plus 32 weeks PR+BOC followed by based therapy and 12 weeks of PR.
NCT01471717 ↗	Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects	Completed	Bristol-Myers Squibb	Phase 1/Phase 2	2011-10-01	This study is designed to evaluate the potential for a pharmacokinetic drug-drug interaction between INX-08189 and Victrelis, a Direct Acting Antiviral (DAA).
NCT01912495 ↗	Dutch Acute HCV in HIV Study (DAHHS)	Completed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 2	2013-08-01	Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds at week 4. The primary hypothesis of this study is that the subset of patients with a Rapid Viral Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.

Clinical Trial Conditions for VICTRELIS

Condition Name

Condition Name for VICTRELIS
Intervention	Trials
Hepatitis C, Chronic	4
Hepatitis C	2
Hepatitis C Infection	2
Hepatitis C,	1

Condition MeSH

Condition MeSH for VICTRELIS
Intervention	Trials
Hepatitis C	8
Hepatitis	7
Hepatitis A	6
Hepatitis C, Chronic	4

Clinical Trial Locations for VICTRELIS

Trials by Country

Trials by Country for VICTRELIS
Location	Trials
United States	3
Netherlands	2
Hungary	1

Trials by US State

Trials by US State for VICTRELIS
Location	Trials
Ohio	1
Minnesota	1
California	1

Clinical Trial Progress for VICTRELIS

Clinical Trial Phase

Clinical Trial Phase for VICTRELIS
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for VICTRELIS
Clinical Trial Phase	Trials
Completed	6
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for VICTRELIS

Sponsor Name

Sponsor Name for VICTRELIS
Sponsor	Trials
Merck Sharp & Dohme Corp.	4
Onze Lieve Vrouwe Gasthuis	1
Radboud University	1

Sponsor Type

Sponsor Type for VICTRELIS
Sponsor	Trials
Other	11
Industry	6
U.S. Fed	1

Victrelis (boceprevir): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is Victrelis and what indication did it target?

Victrelis is the brand name for boceprevir, an oral direct-acting antiviral (DAA) in the hepatitis C treatment class of NS3/4A protease inhibitors. It was developed for treatment of chronic hepatitis C virus (HCV), historically in combination with peginterferon alfa and ribavirin (the interferon-based standard of care at the time of approval).

What clinical trial evidence supported approval?

Victrelis entered late-stage development through pivotal Phase 2 and Phase 3 programs designed to evaluate sustained virologic response (SVR) as the primary efficacy endpoint. In interferon-based regimens, boceprevir was studied as an add-on to improve viral clearance compared with interferon and ribavirin alone.

Key clinical trial patterns (efficacy endpoints and regimen structure)

• Population: Patients with chronic HCV (predominantly genotype cohorts in line with then-standard stratification).
• Comparator: Peginterferon alfa plus ribavirin with or without boceprevir.
• Primary endpoint: SVR (viral RNA undetectable at follow-up timepoint after treatment completion).
• Mechanism-driven rationale: NS3/4A protease inhibition increases depth and speed of viral suppression when used early in combination therapy.

Trial results (high-level)

The pivotal program established that adding boceprevir to peginterferon alfa/ribavirin increased SVR rates versus the interferon-plus-ribavirin backbone alone, across the studied genotype and regimen strata, with dosing schedules and response-guided strategies used to manage duration and treatment intensity. (Trial design and endpoints are consistent with the FDA review record and label summaries for boceprevir.) [1], [2]

What is the clinical trials update after launch?

Victrelis did not become the backbone of later interferon-free HCV regimens. After the market shift to interferon-free DAAs (including newer protease inhibitors, NS5A inhibitors, and polymerase inhibitors), boceprevir’s development and uptake declined sharply. The post-approval landscape is characterized by:

• Reduced clinical emphasis as interferon-free combinations rapidly displaced interferon-era regimens.
• De-emphasis in late-line therapy as newer combinations delivered higher cure rates with better tolerability and simpler dosing.

How did regulatory status and labeling evolve?

Victrelis received FDA approval in the interferon-based era and came with labeling specific to:

• Use in combination with peginterferon alfa and ribavirin.
• Guidance on treatment duration and management of viral response.
• Warnings reflecting the interferon and ribavirin backbone risks, including hematologic and hepatic considerations typical for that regimen era.

The FDA labeling record is the controlling reference for regimen and safety language during its commercial lifecycle. [1], [2]

---

What did the market look like when Victrelis launched?

Boceprevir launched into a high-need segment: chronic HCV treatment required improved outcomes over interferon and ribavirin alone. Protease inhibitors became the first wave of interferon-era DAAs that materially increased SVR rates and reduced treatment failure.

Market dynamics that determined uptake

Victrelis’ commercial trajectory was shaped by four market forces:

1. Competitive DAA class timing: Competing protease inhibitors and combo strategies rapidly emerged.
2. Interferon-era constraints: Treatment required peginterferon and ribavirin, which limited adoption due to tolerability.
3. Rapid substitution risk: The industry moved quickly to interferon-free regimens with higher cure rates and simpler administration.
4. Formulary and guideline velocity: Once interferon-free standards were adopted, interferon-based add-on DAAs lost prescriber volume.

Commercial implication

Even with strong relative efficacy in interferon-based regimens, Victrelis faced structural headwinds: it was dependent on an interferon backbone that the market abandoned within a short window once interferon-free DAAs became standard. [3]

---

Where did Victrelis sit in the competitive landscape by mechanism?

Boceprevir competed in the NS3/4A protease inhibitor class used with peginterferon and ribavirin. The competitive set included other protease inhibitors and evolving multi-target regimens.

Mechanism placement

• Victrelis (boceprevir): NS3/4A protease inhibitor
• Backbone requirement: peginterferon alfa plus ribavirin in label-supported regimens. [1]

---

How is the current market characterized?

Victrelis is an older DAA whose market presence has largely been displaced by interferon-free regimens. The practical market reality is:

• Prescribing has shifted to newer regimens that do not require interferon.
• Remaining utilization tends to be limited to specific clinical scenarios where older regimens still appear in legacy formularies, special populations, or historical continuity.

The FDA product labeling and the regulatory context reflect an indication framework rooted in the interferon era, which is not aligned with modern interferon-free standards. [1], [2]

---

Market analysis: What drives demand and what caps it?

Demand drivers (what can still keep residual volume)

• Legacy formulary access in some systems that retain historic DAAs.
• Treatment continuity for patients already started on compatible regimens in transitional settings.
• Local practice variance where newer agents might not be immediately adopted due to procurement cycles.

Demand caps (what limits long-term expansion)

• Interferon-free substitution: Newer regimens provide higher cure rates with better tolerability and simpler dosing.
• Guideline turnover: Clinical guidelines shifted quickly to interferon-free therapy, reducing incentive to use protease inhibitors requiring interferon.
• Reduced clinical testing relevance: As interferon-based DAAs aged out of clinical research agendas, prescriber confidence and institutional protocols moved on.

---

What is the market projection for Victrelis?

Victrelis’ near- to long-term outlook is defined by decreasing relevance in the modern standard of care. A forward-looking projection framework for an older interferon-era DAA is constrained to residual demand and legacy usage.

Projection (directional)

• Overall trajectory: Declining unit demand versus modern DAAs.
• Market share: Decreasing as newer interferon-free regimens dominate.
• Expected growth: No sustained growth base; any remaining growth depends on isolated legacy prescribing patterns rather than broad market adoption.

Given the drug’s dependence on an interferon backbone, and the market’s rapid pivot to interferon-free cures, the realistic projection is continued contraction with limited rebound potential. [3]

Commercial outlook by time horizon (directional)

• 0 to 2 years: Persistent decline; residual use concentrated in legacy contexts.
• 2 to 5 years: Minimal residual volume; continued displacement by standard-of-care regimens.
• 5+ years: Near-stationary low utilization or discontinuation-driven scarcity effects depending on supply and payer policy.

---

What are the key safety and risk considerations impacting adoption?

Victrelis use in its label context required peginterferon and ribavirin, which introduces key risks tied to the backbone:

• Hematologic toxicity risks (e.g., anemia and neutropenia) associated with interferon/ribavirin regimens.
• Drug interaction and contraindication considerations typical for protease inhibitor use within combination regimens.

These factors matter commercially because interferon-free regimens reduced the tolerability burden and simplified risk management. The label remains the controlling reference for regimen-specific precautions. [1], [2]

---

Key Takeaways

• Victrelis (boceprevir) is an NS3/4A protease inhibitor designed for peginterferon alfa plus ribavirin combination therapy in chronic HCV during the interferon-era standard of care. [1]
• Pivotal studies established improved SVR outcomes versus interferon/ribavirin alone, using SVR as the primary efficacy endpoint. [1], [2]
• Post-launch clinical and market relevance declined as interferon-free DAA regimens replaced interferon-based therapy, structurally limiting Victrelis demand growth. [3]
• Market projection: continued downward trajectory with residual legacy use; no credible growth driver in modern HCV standards.

---

FAQs

1) Is Victrelis used in current first-line chronic HCV therapy?

Victrelis is not aligned with the dominant modern standard of care, which is interferon-free. Its label framework is rooted in peginterferon and ribavirin combination use, limiting its role in current first-line practice. [1], [3]

2) What endpoint did pivotal trials use to prove efficacy?

The pivotal program used SVR (sustained virologic response) as the primary efficacy endpoint, consistent with FDA review documentation for boceprevir’s regimen. [1], [2]

3) Why did Victrelis lose share even though it improved cure rates versus interferon alone?

Victrelis depended on interferon and ribavirin. Interferon-free DAAs displaced the backbone requirement quickly, reducing the addressable patient population for interferon-era protease inhibitors. [3]

4) What is the core drug class mechanism of Victrelis?

Victrelis is an NS3/4A protease inhibitor that blocks HCV protease function when used as part of combination therapy. [1]

5) What is the most likely direction of Victrelis revenues going forward?

A continued declining trajectory is the base case because current HCV treatment standards rely on interferon-free combinations rather than peginterferon plus ribavirin add-ons. [3]

---

References

[1] U.S. Food and Drug Administration. Victrelis (boceprevir) Prescribing Information. FDA label.
[2] U.S. Food and Drug Administration. FDA Approval Package for Victrelis (boceprevir). Review documents.
[3] Industry and guideline transition literature on the shift from interferon-based HCV regimens to interferon-free direct-acting antivirals (DAAs), reflecting rapid market displacement of first-wave protease inhibitors.